Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03584217
Other study ID # 16-1752
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 1, 2018
Est. completion date October 30, 2023

Study information

Verified date August 2023
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Type 2 diabetes (T2D) in youth is increasing in prevalence in parallel with the obesity epidemic. In the US, almost half of patients with renal failure have DKD, and ≥80% have T2D. Compared to adult-onset T2D, youth with T2D have a more aggressive phenotype with greater insulin resistance (IR), more rapid β-cell decline and higher prevalence of diabetic kidney disease (DKD), arguing for separate and dedicated studies in youth-onset T2D. Hyperfiltration is common in youth with T2D, and predicts progressive DKD. Hyperfiltration may also be associated with early changes in intrarenal hemodynamic function, including increased renal plasma flow (RPF) and glomerular pressure. Despite the high prevalence and gravity of DKD in youth-onset T2D, widely effective therapeutic options are lacking. The investigators' preliminary data support a strong association between IR and hyperfiltration in youth-onset T2D, but the pathology contributing to this relationship remains unclear. A better understanding of the pathophysiology underlying hyperfiltration and its relationship with IR is critical to inform development of new therapeutics. The investigators' overarching hypotheses are that: 1) hyperfiltration in youth-onset T2D is associated with changes in intrarenal hemodynamics, resulting in increased renal oxygen demand, 2) the demand is unmet by the inefficient fuel profile associated with IR (decreased glucose oxidation and increase free fatty acid [FFA] oxidation), resulting in renal hypoxia and ultimately renal damage. To address these hypotheses, the investigators will measure peripheral insulin sensitivity, adipose insulin sensitivity (FFA suppression), glomerular filtration rate (GFR), RPF, and renal oxygenation in youth with T2D (n=60), obesity (n=20) and in lean (n=20) controls. To further investigate the mechanisms of renal damage in youth with T2D, two optional procedures are included in the study: 1) kidney biopsy procedure and 2) induction of induced pluripotent stem cells (iPSCs) to assess morphometrics and genetic expression of renal tissue.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date October 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 21 Years
Eligibility Inclusion Criteria: - Obese youth with and without T2D (=54 kg) and lean controls - Age 12-21 years - Weight <300 lbs., no implanted metal devices - HbA1c < 11% and no recent diabetic ketoacidosis or hyperosmolar hyperglycemia - No anemia - BMI >5th percentile for lean controls Exclusion Criteria: - T2D onset (diagnosis) > 18 years of age - Prepubertal - eGFR <60ml/min/1.73m2 or creatinine > 1.5mg/dl or history of ACR=300mg/g - ACE inhibitors, angiotensin receptor blockers (ARB), diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides, procaine, thiazosulfone or probenecid. - Seafood or iodine allergy - Pregnancy - MRI scanning contraindications (claustrophobia, implantable devices, >300 lbs) Additional exclusion criteria for participants undergoing optional kidney biopsy: - Evidence of bleeding disorder or complications from bleeding - Use of aspirin, NSAIDS or other blood thinner that cannot be safely stopped for a sufficient time period before and after the biopsy so as to add no additional risk of bleeding - Blood urea nitrogen (BUN) > 80 gm/dL - INR > 1.4 - PTT > 35 seconds - Hemoglobin (Hgb) < 10 mg/dL - Platelet count < 100,000 / µL - Uncontrolled or difficult to control hypertension (> 150/90 mmHg at the day of biopsy) - eGFR < 40 mL/min/1.73m2 - Single kidney (either by history, documented by prior imaging or ultrasound performed prior to the biopsy) - > 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter determined by ultrasound performed prior to the biopsy. - Kidney size: One or both kidneys < 9 cm - Hydronephrosis or other important renal ultrasound findings such as significant stone disease - Any evidence of a current urinary tract infection as indicated on day of biopsy - Clinical evidence of non-diabetic renal disease - Positive urine pregnancy test or pregnancy

Study Design


Intervention

Drug:
Aminohippurate Sodium Inj 20%
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Iohexol Inj 300 MG/ML
Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Procedure:
Renal Biopsy
Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Podocyte numerical density and number per glomerulus Measured by light microscopy from tissue obtained by renal biopsy 4 hours
Other Foot process width of glomeruli Measured by electron microscopy from tissue obtained by renal biopsy 4 hours
Other Detachment and endothelial fenestration of glomeruli Measured by electron microscopy from tissue obtained by renal biopsy 4 hours
Other Podocyte volume of glomeruli Measured by electron microscopy from tissue obtained by renal biopsy 4 hours
Other Number and identity of RNA in kidney cells Measured from tissue obtained by renal biopsy 4 hours
Other Epigenetic profiling Measured from tissue obtained by renal biopsy 4 hours
Primary Effective renal plasma flow (ERPF) Measured by PAH clearance 4 hours
Primary Glomerular filtration rate (GFR) Measured by iohexol clearance 4 hours
Secondary Insulin sensitivity Measured by hyperinsulinemic-euglycemic clamp 4 hours
Secondary Renal oxygenation Blood oxygen level dependent (BOLD) MRI 60 min
Secondary Renal perfusion Arterial spin labeling (ASL) MRI 10 min
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2